Zacks Investment Management and other institutional investors have recently acquired
new holdings in
Bio-Rad Laboratories, Inc. (NYSE:BIO), while some existing shareholders experienced a
loss of 58% following a stock drop of 4.6%. Despite these losses, the stock witnessed a
surge due to the company's
positive financial performance. However, SWOT analysis suggests potential
growth hurdles for Bio-Rad.
New investments have been made by several companies including Y Intercept Hong Kong Ltd and PEAK6 Investments LLC. Analysts have updated estimates following the release of Bio-Rad's third-quarter results and the stock has been given a consensus recommendation of
Moderate Buy by brokerages. The
price target for Bio-Rad Laboratories has also been raised. The company reported
strong clinical diagnostics in their Q3 2024 earnings call, and beat Q3 earnings and revenue estimates. However, shareholders have endured significant losses over the past three years, pushing the stock
underperformance within the healthcare sector. Bio-Rad had to
cut annual revenue forecast due to
weak demand for diagnostics products. Nevertheless, the company still managed to exceed expectations with a
strong quarterly performance.
Bio-Rad Laboratories Stocks News Analytics from Tue, 18 Aug 2020 16:55:20 GMT to Fri, 13 Dec 2024 06:20:00 GMT -
Rating 0
- Innovation -4
- Information 6
- Rumor -3
